FDA Drug Recalls

Recalls / Class II

Class IID-0095-2025

Product

Diltiazem Hydrochloride Extended-Release Capsules, USP 120 mg, Rx Only, 100 Capsules, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India, NDC 68462-562-01.

Brand name
Diltiazem Hydrochloride
Generic name
Diltiazem Hydrochloride
Active ingredient
Diltiazem Hydrochloride
Route
Oral
NDCs
68462-562, 68462-850, 68462-851
FDA application
ANDA212317
Affected lot / code info
Lot #: 17222470, 17230680, 17222547, Exp. Date 11/30/2024; 17230304, Exp. Date, 12/31/2024; 17230598, Exp. Date, 02/2025.

Why it was recalled

cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.

Recalling firm

Firm
Glenmark Pharmaceuticals Inc., USA
Manufacturer
GLENMARK PHARMACEUTICALS INC., USA
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
750 Corporate Dr, Mahwah, New Jersey 07430-2009

Distribution

Quantity
25584 bottles
Distribution pattern
Nationwide in the USA

Timeline

Recall initiated
2024-11-01
FDA classified
2024-12-03
Posted by FDA
2024-12-11
Status
Ongoing

Source: openFDA Drug Enforcement endpoint. Recall record D-0095-2025. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.